Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Co.

www.bms.com

Latest From Bristol-Myers Squibb Co.

Tough Going Forces Chinese Biotechs To Form Domestic Alliances

Deals among domestic Chinese biotechs are growing fast, reflecting a need to huddle up amid tightening scrutiny over biotech deal-making and an unusually competitive immuno-oncology market.

Deals Research and Development Strategies

Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals

The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.

Clinical Trials Research & Development

Nektar/Bristol Show Promise With Double IO Combo, But Numbers Are Small

Updated data from PIVOT-02 at the ASCO GU meeting suggest a path for accelerated approval of the NKTR-214/Opdivo combination as first-line treatment of patients with PD-L1-negative urothelial cancers.

Clinical Trials Research & Development

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

BioMarin’s focus on rare diseases and gene therapies and expected financial growth make it a logical acquisition target for almost any large pharma, though Biogen, Amgen and Regeneron also offer a beneficial fit for many.

M & A Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register